

INDEX

A

- AAA Ca. *See* Active absorbable algal calcium
- AAS. *See* Amino acid score
- ACE. *See* Angiotensin I-converting enzyme
- Activated partial thromboplastin time (APTT)
 - prolongation, 236–237
 - TT pathways, 236–237
- Active absorbable algal calcium (AAA Ca), 49
- Adequate intake (AI), 375
- Alginates, 91–92
- Alkaline phosphatase (ALP), 430
- Amino acid score (AAS), 308–309
- Angiotensin I-converting enzyme (ACE), 318
- Antiallergic benefit, marine algae
 - allergy, 268
 - compounds, 268–269
 - therapeutic inhibitors
 - macroalgae, 269
 - microalgae, 272–273
 - phlorotannins, 270
 - polysaccharides, 270–271
- Antiallergic compounds
 - phlorotannins, 270
 - polysaccharides
 - marine algae, 270–271
 - porphyran, 271
- Anticancer compounds, marine macroalgae
 - brown algal species, 215
 - carotenoids, 220–221
 - functional foods, 221–222
 - metabolites, 214–215
 - phlorotannins, 218–220
 - plants and terrestrial microorganisms, 214–215
 - sulfated polysaccharides
 - carrageenans, 217–218
 - fucoidan, 216–217
 - monomeric units, 215–216
 - ulvans, 218
 - synthetic drugs and natural products, 214
- Anticancer effect, SPs
 - apoptosis *in vitro*, 397
 - tumor cell proliferation, 397
- Anticoagulant effect, marine algae
 - bioactive substances, 236–237
 - blood coagulation system, 236
 - description, 236
 - heparin, 236, 241
 - organisms, 236
 - phlorotannins, 237–239
 - PT, 241
 - Sargassum thunbergii*, 241
 - SPs, 237, 240
- Anti-human immunodeficiency virus (HIV) activity
- AIDS, 257
- DT1 and DT2, 262–263
- gp120 and gp41, 256
- lectins
 - BCA, 262
 - description, 261
 - Griffithsin, 261–262
- macroalgae, 262
- phlorotannins
 - 6,6'-bieckol, 258
 - Ecklonia cava*, 258
 - Ishige okamunae*, 258
 - tannins, 257
- polysaccharides
 - Adenocystis utricularis*, 260
 - effects, 259
 - fucans, 259–260
 - GFP and GLP, 260
 - Schizymenia dubyi*, 260
 - SPMG, 260–261
 - therapeutic agents, 256
- Antioxidant effect, SPs
 - ABTS radical scavenging, 394–395
 - antioxidant activity, 394–395
 - marine algae, 394
 - natural antioxidants, 395
 - ROS, 394
 - structural features, 394–395

Antiviral effect, SPs

- algal sulfated polysaccharides, 395–396
- fucoidan, 396
- in vitro* and *in vivo* infections, 396
- inhibitory effects, 396
- marine algal polysaccharides, 395–396

APTT. *See* Activated partial thromboplastin time

Asthma

- characteristics
 - airway wall, 282–283
 - inflammation, 281–282
- Ecklonia cava*, 278–279
- factors, 279
- macroalgae
 - Ecklonia cava*, 281–282
 - Eisenia arborea*, 281–282
 - red algal, 282
- mechanism, 280
- microalgae
 - blue-green algae, 282–283
 - use, 282–283
- remedies and failures, 281
- symptoms, 278

B

Biofilm, chronic infection prevention

- agricultural soil enrichment, 404
- anti-biofilm agents, 408
- bacterial cells, 405–406
- bacterial interactions, 405
- carbon-neutral electricity, 407–408
- chemotherapy, 408–409
- diabetic foot ulcer, 411–412
- environmental dangers, 405–406
- eye infection, 412
- fibrosis-associated infections, 404
- formation, 405
- global wound care expenditures, 409
- health care, 408–409
- histological changes, 405–406
- immunity, 412–413
- kidney relevance, 411
- metabolic waste products, 407
- otolaryngologic diseases, 412–413
- periodontal diseases, 409–410
- physiology/growth state, 406–407
- planktonic cells, 407–408
- proinflammatory cytokines, 408
- quorum sensing, 406–407
- surface attachment, 405–406
- synthesis and degradation, 405–406

wound inflammation, 410

Biological activity, SPs

- description, 328–329
- in vitro* studies
 - animals and cell model, 330
 - anticoagulant, 329
 - antioxidant, 329
 - properties, 329
 - sulfate groups, 329–330

Bisphosphonates

- adverse side effects, 419
- osteoporosis, 419

Bone mineral density (BMD), 420

Bone morphogenic proteins (BMPs), 430

C

Ca-mineralization, osteoblastic differentiation

- abnormal bone homeostasis, 430
- ALP levels, 434–436
- anti-inflammatory effects, 431
- BMPs, 430
- CMAP, 432, 433
- fucodiphlorethol G, 434
- fucoidans, 434–436
- marine algae therapeutic potential
 - bone tissue engineering applications, 437–438
 - diet with calcium supplement, 438
- marine compounds, 431
- marine organisms, 430–431
- microalgae and macroalgae, 431
- novel marine metabolites, 431
- osteoblasts and osteoclasts, 430
- phlorotannins, 432–434
- triphlorethol-A, 434

Capsosiphon fulvescens-polysaccharides (Cf-PS)

- antioxidant activities, 180
- cell proliferation, 180–181
- description, 180
- ERK1/2 activation, IEC-6 cells
 - cross talk model, signaling pathways, 186, 188
- EGFR transactivation, 185–186
- MAPK protein expression, 185
- proliferation, 185, 186
- Wnt signaling, 186, 187
- IEC-6 cell proliferation
 - agarose gel electrophoresis, 181–182
 - microscopy analysis, 181–182, 183
 - MTS assay, 181–182, 183

PCNA protein expression, 181–182, 183
 sea vegetables, 181
 signaling pathways, 180–181
 Wnt signaling components
 cell proliferation and division, 182
 expression measurement, 184
 IEC-6 cells, 184
 time-course experiment, 182
 Cardiolum, 94
 Cardiovascular diseases (CVD)
 lipids, 344
 risk, 340
 Carotenoids
 astaxanthin and fucoxanthin, 220–221
 biological activities, 221
 Carrageenans
 antioxidant and antitumor activities,
 217–218
 l-carrageenan, 217–218
 Chlorophyta, 73–74
 Coccolith matrix acidic polysaccharide
 (CMAP), 432
 Cyclooxygenase-2 (COX-2), 343

D

Dietary Reference Intakes (DRIs), 375
 Diet with calcium supplement
 bone mineral loss, 438
 ingredients, 438
 mineral-rich supplement, 438
 osteoporosis, 438

E

EAA. *See* Essential amino acids
 EGFR. *See* Epidermal growth factor receptor
 Eicosapentaenoic acid (EPA)
 ALA conversion, 341
 DHA, 343
 Epidermal growth factor receptor (EGFR)
 signaling pathway, 185
 transactivation, 185–186
 ERK1/2. *See* Extracellular signal-regulated
 kinase 1/2
 Essential amino acids (EAAs)
 levels, 307–308
 ratio, 307–308
 Estimated Average Requirement (EAR),
 375
 Extracellular signal-regulated kinase
 1/2 (ERK1/2)
 activation, IEC-6 cells

cross talk model, signaling pathways,
 186, 188
 EGFR transactivation, 185–186
 MAPK protein expression, 185
 proliferation, 185, 186
 Wnt signaling, 186, 187
 pathway, 181

F

Female health, beauty and longevity,
 marine algae on
 anticancer activity
 apoptosis, 43–44
 breast cancer, 43
 cervical cancer, 44
 chemopreventive agents, 45
 estrogen-dependent cancers, 44
 antiobesity activity
 detrimental effects, 46
 foods and pharmaceuticals, 48–49
 fucoxanthin, 48
 soluble, insoluble and total fiber,
 46–48
 synthetic antiobesity agents, 46
 antiosteoporosis activity
 AAA Ca, 49
 description, osteoporosis, 49
 dietary fucoxanthin, 49
 antiviral activity, 45–46
 Asia, 42
 marine organisms, 42
 nutritional value and health benefits, 42
 skin whitening activity
 advantages, 50–51
 tyrosinase inhibition, 50
 Fucoidans
 anticoagulant and antithrombotic activity
 Ecklonia cava, 168–169
 fermentation process, 169
 heparin, 167–168
 mechanism and molecular interaction,
 168–169
 Sargassum fulvellum, 169
 anti-inflammatory activity
 connective tissue destruction, 173
 definition, 172
 LPS-stimulated RAW 264.7 cells, 172
 antiproliferative/antitumor/anticancer
 activity
 biological activities, 169, 170
 chemopreventive agents, 170
 inhibitory effects, 169

Fucoidans (*cont.*)

- antitumor and antimetastatic activities, 217
- antiviral activity, 173
- biological properties, 166–167
- chemical structure, 165
- description, 216–217
- fucoxanthin and phlorotannins, 164
- immunomodulatory activity
 - activated splenocytes, 171
 - dendritic cells, 171–172
 - MMP-9, 172
- industrial applications, 173–174
- Laminaria*
 - anticancer properties, 92–93
 - antioxidant activity, 93
 - antivirus effects, 92
 - cholesterol content, reduction, 93–94
 - molecular mass and sulfate content, 93
 - oligosaccharides, 93–94
- MMPs (*see* Matrix metalloproteinase inhibitors (MMPis))
- polysaccharides
 - description, 164–165
 - functional, 164
- purification
 - enzyme-assisted extraction
 - technique, 166
 - marine algae, 165–166
 - solvent extraction process, 166
- restenosis, 173
- seaweeds and bioactive components, 164
- toxicology, 173

Fucoxanthin

- antiangiogenic activity
 - angiogenesis, 121–122
 - pathological conditions, 121–122
 - siponaxanthin, 122
- anticancer activity
 - anti-adult T-cell leukemia effects, 117–118
 - apoptosis, 117
 - pharmaceutical and food industries, 118
 - vs.* siponaxanthin, 117–118
- anti-inflammatory activity
 - inhibition, proinflammatory mediators, 118–119
 - macrophage function, 118
 - scientific analysis, 118–119
- antiobesity activity
 - adipocyte differentiation, 120
 - advantages, 120
 - description, obesity, 119

WAT, 119–120

xanthigen, 119–120

antioxidant activity

- applications, 116
- cytoprotective effect, 116
- free radical-mediated process, 115
- radical scavenging, 116
- synthetic antioxidants, 115
- health beneficial effects, 112, 113
- marine algae
 - food diets and traditional remedies, 112
 - pigmentation, 112–113
- marine organisms, 112
- neuroprotective effect
 - natural and synthetic compounds, 120–121
- neurite outgrowth, 121
- wakame, 121

osteoclastogenesis, 122–123

profiles and bioavailability

- absorption and esterification, 114–115
- adverse side effects, 115
- amarouciaxanthin A, 114–115
- chemical structures, 113–114
- skin protective effect, 122

Fucoxanthin-rich seaweed extract

(Fx-SEE), 202

Fx-SEE. *See* Fucoxanthin-rich seaweed extract

G

Glucose transporter 2 (GLUT2), 209

GLUT2. *See* Glucose transporter 2

Glutathione (GSH)

description, 150

levels

JNK inhibitor, 158

measurement and analysis, 150, 155

Green water technique, 79–80

GSH. *See* Glutathione

H

Herpes simplex virus (HSV)

classification, 246

infection, 246

reproduction, 246–247

Histone deacetylases (HDACs), 420–421

Hizikia fusiformis-polysaccharide (Hf-PS-1),

protective effects

botanical products, 145

description, 145

- ethanol-induced gastric damage, rats
 caspases, 149, 150
 composition, powdered sample, 146, 147
 DNA fragmentation, 149, 151
 electrophoresis bands, 146, 148
 epithelial cells, 148–149
 hemorrhaging, 146–148
 intestinal surface, stomach samples, 146–148
 long-term *vs.* short-term experiments, 146–148
 oxidative stress, 150–151
 pharmaceutical products and side effects, 146
 purification procedures, 146, 147
 seaweed compounds, 146
 gastrointestinal disorders and drugs, 144–145
 IEC-6 cells, ethanol-induced injury
 cell viability assays, 151–152, 153, 154
 downregulation, JNK, 152–157
 IGF-IR and Shc phosphorylation, 151–152, 155
 methanol and ethanol extracts, 144
 seaweeds and extracts, 145
 HPV. *See* Human papilloma virus
 HSV. *See* Herpes simplex virus
 Human papilloma virus (HPV)
 carrageenan, 45–46
 infection and vaccine, 45
- ### I
- IEC-6. *See* Intestinal epithelial cell line 6
 IGF-IR. *See* Insulin-like growth factor-I receptor
 Immunostimulating effect, SPs
 anti-inflammatory activities, 397
 immune system, 397
 macrophages, 396–397
 Insulin-like growth factor-I receptor (IGF-IR)
 phosphorylation, 151–152, 155
 signaling pathways, 158
 Intestinal epithelial cell line 6 (IEC-6)
 ERK1/2 activation
 cross talk model, signaling pathways, 186, 188
 EGFR transactivation, 185–186
 MAPK protein expression, 185
 proliferation, 185, 186
 Wnt signaling, 186, 187
 proliferation
 agarose gel electrophoresis, 181–182
 microscopy analysis, 181–182, 183
 MTS assay, 181–182, 183
 PCNA protein expression, 181–182, 183
 sea vegetables, 181
- ### J
- JNK. *See* Jun N-terminal kinase
 Jun N-terminal kinase (JNK)
 activation, 150–151
 downregulation, ethanol-induced toxicity
 Hf-PS-1's protective mechanism, 155–157
 IGF-IR activation, 152–155
 inhibitor SP600125, 155
 MAPK signaling pathway, 152–155, 156
 phosphorylation, 152–155, 156
- ### K
- 16 kDa fucoidan, 136–137
 Kelp. *See* *Laminaria*
- ### L
- Laminaria*
 biological properties
 alginates, 91–92
 cardiolam, 94
 fucoidan, 92–94
 laminarin, 94
 medicinal benefits, 91
 chemical properties
 alginic acid, 90
 biologically active substances, 90
 chromists, 88–90
 medicinal properties, 90
 mineral extraction, 90
 vitamins, 90–91
 description, 86
 life cycle, 88, 89
 nutrients, 86
 physical properties
 fucoxanthin, 87–88
 genomic information, 87–88
 structure, 87
Laminaria japonica (LJ)
 antidiabetic effects
 algal polysaccharides, 205
 aqueous extract (LJE), 206
 diabetes, 205
 glucose absorption, 206–207
 glucose intake, Caco-2 cells, 207–209

Laminaria japonica (LJ) (cont.)

- glucose transmission, Caco-2 cells, 207–209
- oral carbohydrate tolerance test, 209
- phloridzin, 207–209
- postprandial blood glucose level, 206–207
- rhizoid, 206
- SGLT1 and GLUT2, 209
- structure, glucose transmission test, 207, 208
- antiobesity effects
 - active component, 205
 - fucoxanthin, 201
 - Fx-SEE, 202
 - NSK and TK, 202–203
 - obesity, 200–201
 - sodium alginate, 202
 - TK, 202
 - wakame lipids (WLs), 201–202
- description, 200
- use, 200, 210
- Laminarin, 94
- Lipids
 - phospholipids and sterols, 11
 - PUFAs, 10–11
- LJ. *See Laminaria japonica*
- Low-density lipoprotein (LDL) oxidation, 359

M

MAA. *See* Mycosporine-like amino acids

Macroalgae

- active components, 452
- alkaline phosphatase (ALP), 450
- apoptotic cell death, 449–450
- bone marrow cell coculture, 449–450
- carotenoid fucoxanthin, 449–450
- Ecklonia cava*, 281–282
- Eisenia arborea*, 281–282
- ovariectomized group, 450
- rat femoral-diaphyseal tissues, 449
- red algal, 282
- Sargassum fusiforme* (SME), 449–450, 451
- Sargassum horneri*, 449

MAPKs. *See* Mitogen-activated protein kinases

Marine algae

- active compounds, 419
- bone tissue engineering applications
 - calcium phosphate compounds, 437
 - Corallina officinalis*, 437
 - graft materials, 437

- hydroxyapatite ceramic granules, 437
- inorganic calcium sources, 437–438
- microporous structure, 437

brown macroalgae

- anti-HSV activity, 249–250
- fucoidans, 248–249

colorectal cancer

- active compounds, 231
- brown algae, 230–231
- description, 229
- development, 229–230
- fucoxanthin, 230
- glycoprotein, 230

description, 226

diet with calcium supplement

- bone mineral loss, 438
- ingredients, 438
- mineral-rich supplement, 438
- osteoporosis, 438

environment, 246

gastricstomach cancer

Capsosiphon fulvescens, 228

description, 227

differences, 227–228

fucoidan, 228

Laminaria japonica, 228–229

porphyran, 228

prevention, 228

gastrointestinal tract cancer, 227

green macroalgae, 250

herpes, 246

microalgae

HIV-1, 250–251

Spirulina platensis, 250–251

mineral extraction, 420

nutritional value, 226

pharmaceutical research, 226

purposes, 226

red, green and brown, 419

red macroalgae

galactans, 247–248

polysaccharide and xylomannans, 247

Polysiphonia denuate, 246–247

Marine algal sources

antibacterial screening

chlorophyta, 73–74

macroalgae classification, 73

phaeophyta, 73

rhodophyta, 73

antimicrobial potentials, 72

bioactive compounds

bromoditerpenes, 74–75

- halogenated furanones, 75
- lectins, 75–76
- phlorotannins, 74
- sesquiterpenes, 74
- biofilm/antifouling bacteria, controlling, 77, 79
- fish bacterial disease, treatment
 - antibacterial activity, 80
 - drug resistance, 79
 - QS, 79–80
- human pathogenic drug/multidrug-resistant strains
 - antimycobacterial activity, 77, 78
 - methanol extracts, 76–77
 - solvents and extraction method, 76
- infectious agents, 72
- therapeutics, 73
- Marine algal sterols. *See* Sterols
- Marine collagen peptides (MCP), 420
- Marine compound
 - BMD, 420
 - mineral extraction, marine algae, 420
 - osteoblast differentiation
 - HDACs, 420–421
 - largazole, 421
 - MCP, 420
 - metaphyseal tissues, 422
 - norzoanthamine, 421–422
 - prevalent chronic inflammatory diseases, 422
 - osteoclast differentiation
 - bislyngbyaside, 423
 - bolinaquinone, 423
 - fucoxanthin, 423
 - ikarisoside A, 423
 - inhibitor, 422
 - symbioimine, 423
- Marine edible algae, disease prevention
 - cancer prevention, 36–37
 - food health promotion
 - ancient times, 30
 - daily consumption, 30–31
 - nutrition facts, 30–31, 32
 - human diet and chronic diseases, 30
- MetS
 - description, 34–35
 - prevention, 35–36
- NCDs, 31
- Matrix metalloproteinase-9 (MMP-9), 172
- Matrix metalloproteinase inhibitors (MMPis)
 - fucoidans
 - antiproliferative action, 137–138
 - chemical structure, 135–136
 - Costaria costata*, 137–138
 - inhibitory effects, 137–138
 - 16 kDa fucoidan, 136–137
 - photoaging, 135–136
 - therapeutic ability, 136–137
 - MMPs and TIMPs, 130
 - phlorotannins
 - chemical structures, 131–133
 - dieckol and eckol, 133–134
 - Ecklonia* and *Eisenia*, 135
 - eckol and dieckol, 135
 - formation, 131–133
 - functional groups, 133–134
 - osteosarcoma differentiation, 133–134
 - phloroglucinol, 134–135
 - skin wrinkling, 134–135
 - scientific investigations, 138–139
 - seaweeds/marine macroalgae, 131
- Matrix metalloproteinases (MMPs)
 - cell proliferation and metastasis, 137–138
 - description, 130
 - functional groups, 133–134
 - photoaging, 134–136
- Metabolic syndrome (MetS)
 - description, 34–35
 - prevention
 - high blood pressure, 35
 - wakame, 35–36
- MetS. *See* Metabolic syndrome
- Microalgae
 - antiallergic properties, 272–273
 - blue-green algae, 282–283
 - in vitro* experiments, 448–449
 - marine invertebrates, 447
 - marine resources, 272
 - norzoanthamine structure, 448–449
 - symbioimine structure, 447, 448
 - use, 282–283
- Micro and macroalgal consumption on
 - photoprotection
 - food and fuel, 288
- macroalgal foods
 - Alaria esculenta* and *Laminaria digitata*, 294
 - blue-green algae, 293
 - irish moss, 293
 - lettuce, 293–294
 - MAA, 293
 - proteins and peptides, 292–293
 - purple laver, 292
 - seaweeds, 293

Micro and macroalgal consumption on
 photoprotection (*cont.*)
 marine environment, 288
 microalgal foods
 Arthrospira platensis/*Spirulina platensis*,
 291–292
 Chlorella, 292
 Phaeodactylum tricornutum, 292
 photoprotection, 288–289
 UV, photodamage and photoprotection
 description, 289
 ERK and JNK, 290
 ozone layer, 291
 RNS and ROS, 289–290
 Mineral bioavailability
 definition, 385
 nutrient synergistic/antagonistic
 interactions, 385
 reciprocal antagonistic/synergic
 behavior, 386
 Mitogen-activated protein kinases (MAPKs)
 mammalian cells, 185
 protein expression, 150–151, 153, 185
 signaling pathway, 152–155, 156,
 185–186
 MMP-9. *See* Matrix metalloproteinase-9
 MMPis. *See* Matrix metalloproteinase
 inhibitors
 MMPs. *See* Matrix metalloproteinases
 Mycosporine-like amino acids
 (MAA), 293

N

NCDs. *See* Noncommunicable diseases
 Noncommunicable diseases (NCDs), 31
 Nonshaved kombu (NSK)
 and HFD, 202–203
 and TK, inhibitory activities
 (*see* Tororokombu (TK))

O

Osteoclast differentiation
 bone loss, 444
 drug resistance, 444–445
 macroalgae (*see* Macroalgae)
 microalgae (*see* Microalgae)
 osteoblasts, *in vitro*
 cell viability, 447
 cervical dislocation, 446
 femoral and tibial bone marrow cells,
 446–447

macrophage colony-stimulating
 factor, 446
 mouse calvarial cells, 447
 multinucleated cells, 447
 myeloid hemopoietic lineage, 446
 osteoporosis-related fracture prevention,
 445
 parathyroid hormone, 445
 pharmacological and nutritional factors,
 444
 postmenopausal osteoporosis, 445
 trench-digging cells, 445
 Osteoporosis treatment
 bisphosphonates, 419
 bone formation and resorption, 418
 bone homeostasis, 418
 elderly age, 418
 estrogen therapy, 418–419
 marine algae
 active compounds, 419
 red, green, and brown, 419
 marine compound
 bone mineral density (BMD), 420
 mineral extraction, marine algae, 420
 osteoblast differentiation, 420–422
 osteoclast differentiation, 422–423
 osteoblast and osteoclast cells, 418
 prevention and treatment, 418–419
 Otolaryngologic diseases, 412–413

P

Peptide, marine microalgae
 anticancer activity, 318–319
 antihypertensive activity
 ACE, 318
 Chlorella, 318
 antioxidant activity
 hydrolysis, 317
 synthetic, 317
 therapeutic modalities, 317–318
 application, 314–315
 bioactivity
 Arthrospira, *Chlorella* and *Dunaliella*
 salina, 316–317
 description, 316
 cultivation, 314–315
 effects
 alcohol, 319
 bioactive, 317, 319
 NIPP-1 and NIPP-2, 319, 320
 human food sources composition,
 315–316

- Peroxisome proliferator-activated receptors (PPAR- α), 341
- Phaeophyta, 73
- Phlorotannins
- antiallergic effects, 105
 - anticancer effects
 - antiproliferative activity, 104
 - inhibition, cancer metastasis, 104–105
 - antidiabetic effects, 106–107
 - anti-inflammatory effects, 106
 - antioxidant effects
 - bioresource, 99–102
 - free radical scavenging ability, 102, 103
 - oxidative stress, 99–102
 - photoprotective ability, 102–104
 - antiproliferative activity, 219–220
 - classification, 237–238
 - definition, medicinal foods, 98
 - derivatives, 237–238, 239
 - dioxynodehydroeckol, 218–219
 - MMPs (*see* Matrix metalloproteinase inhibitors (MMPs))
 - secretion and concentration, 99
 - structures, 98–99, 101
- Phytochemicals
- flavonoids and carotenoids, 10
 - halogenated compounds, 10
 - phlorotannins/polyphenols, 9–10
 - secondary metabolites, 9–10
- Planktonic cells, 407–408
- Polysaccharides
- alginate acid, 8
 - carrageenans, 8
 - fucoidan, 9
 - laminarin, 8–9
 - marine algae, 270–271
 - porphyran, 271
 - sulfated, 7
 - ulvan, 9
- Polyunsaturated fatty acids (PUFAs)
- composition
 - environmental pollution, heavy metals, 347
 - FA profiles, 347–350
 - Fucus serratus*, 347
 - Laminaria japonica*, 347
 - lipid content, 350
 - nitrogen deficiency, 347
 - red seaweeds, 350
 - wild and cultured strains, 347
 - distribution
 - FA compositions, 350
 - TAGs, 350
 - health importance
 - biochemical pathways, 341
 - biological activities, 343
 - cyclooxygenase-2 (COX-2), 343
 - desaturases and elongases, 341
 - diet, 343–346
 - dispensability, 340–341
 - EPA and DHA, 343
 - metabolic transformation, 341
 - pleiotropic metabolic effects, 341
 - ω -6/ ω -3 ratio, 346
- Probiotics, 24–25
- Proteins and amino acid
- bioavailability, digestion and absorption
 - digestion, 302
 - mucosal cells, 302–303
 - quality, 302
 - transport, 302
 - requirements
 - defined, 299–300
 - nitrogen balance, 300
 - nitrogen status, 298–299
 - pregnancy and lactation, 299–300
 - role
 - cancer, 302
 - deficiency, 301
 - enzymes deficiency, 298
 - nitrogen waste, 301
 - seaweeds, 303–309
- Prothrombin time (PT)
- APTT, TT, 241
 - prolongation, 241
- PT. *See* Prothrombin time
- PUFAs. *See* Polyunsaturated fatty acids
- Q**
- QS. *See* Quorum sensing
- Quorum sensing (QS)
- mechanism, 79
 - microalgae, 79–80
- R**
- Reactive nitrogen species (RNS), 289–290
- Reactive oxygen species (ROS), 289–290, 394
- Recommended daily allowances (RDA)
- vitamin-dependent function, 359
 - vitamin E, 360
 - vitamins B₁ and B₂, 360
- Recommended daily intakes (RDIs)
- iodine content, 378

Recommended daily intakes (RDIs) (*cont.*)
 macroelements and microelements, 376
 seaweed, 372, 380
 Recommended nutrient intakes (RNIs), 375
 Retinol equivalent (RE), 360
 Rhodophyta, 73
 RNS. *See* Reactive nitrogen species
 ROS. *See* Reactive oxygen species

S

Sea lettuces

culinary use
 animals and humans, 59
 Hawaii, Cuba and Philippines, 59–60
 Japan, 59
 laverbread, 60
 description, 58–59
 fatty acids, 63–65
 lipids, 63
 minerals
 classification, 67
 contents, 67
 iodine, 68
 polysaccharides
 family, 60–61
 ulvan, 61, 62
 water soluble and insoluble fibers, 60–61
 protein and amino acids
 bioactive lectins, 62
 compositions, 62, 63
Ulva reticulata and *Ulva lactuca*, 62
 seaweeds and health benefits, 58
 vitamins
 contents, 65, 66
 vitamin B complex, 65–66
 vitamin C, 66
 vitamin E, 66–67

Seaweed

bioactive peptides, sources
 ACE-inhibitory peptides, 331
 antihypertensive agents, 333–334
 description, 330–331
 heart diseases, 331
 proteins extraction, 331–332
 wakame, 332–333
 dietary fiber and digestive health benefits
 colorectal cancer, 23
 description, 21–22
 gastrointestinal inflammation, 24
 probiotics, 24–25
 types, soluble fiber, 22–23
 food, 18

human nutrition, enhancement
 carbohydrates, 19
 lipids, 20
 minerals, 21
 proteins, 19–20
vs. vegetables, 18–19
 vitamins, 20–21
 nutritional assessment
 biochemical aspects, 327
 brown and red, 326
 dietary fiber, 327
 environment, 327
 minerals, 327
 nutritional health benefits
 glycemic control, 26–27
 lipid absorption and cardiovascular
 diseases, reduction, 26
 obesity reduction, 25–26
 phenolic molecules, 25
 sulfated polysaccharides
 biological activity, 328–330
 preparation, 328
 role, 328
 use, 326
 Seaweed lipids, nutraceuticals
 marine microalgae
 DHA production, 351
 human lymphocytes, 350–351
 microalgal lipids, 351
Schizochytrium mangrovei, 351
 thraustochytriacea, 350–351
 PUFAs
 composition, 347–350
 distribution, 350
 health importance, 340–346
 Seaweed minerals, nutraceuticals
 bioavailability
 definition, 385
 nutrient synergistic/antagonistic
 interactions, 385
 reciprocal antagonistic/synergic
 behavior, 386
 concentration factors (CFs), 383
 daily requirements
 iodine content, 378
 RDIs, 382–383
 zinc and manganese, 380
 endogenous factors
 cell wall polysaccharides, 383
 diverse affinity, 384
 iodine uptake mechanism, 384
Palmaria palmata, 383–384
 exogenous factors

- chemical composition, 384–385
- environmental conditions, 384
- physiology and biochemical composition, 385
- Porphyra vietnamensis*, 384
- sorption mechanism, metals, 385
- human body
 - iodine, 372–373
 - iron, 373
 - manganese, 374–375
 - zinc, 374
- requirements, humans
 - chronic nutrition-related diseases, 375
 - DRI, 375
 - recommended daily intakes (RDIs), 376
- Seaweeds and functional food development
 - biochemical composition analysis
 - amino acids, 7
 - lipids, 10–11
 - minerals and vitamins, 11
 - peptides, 6–7
 - phytochemicals, 9–10
 - polysaccharides, 7–9
 - proteins, 5–6
 - species and bioactive compounds, 5, 6
 - challenges, 12
 - classification and biochemical composition, 4
 - cultivation and research, 4–5
 - disease prevention
 - consumer awareness, 2
 - definition, 2–3
 - dietary transitions, 2
 - digestive health, 3
 - energy and sports drinks, 3
 - ω -3 fatty acids, 3–4
 - soy protein, 3–4
 - innovations and chronic diseases, 12–13
 - photosynthetic algae, 4
 - phycocolloid industry, 12
 - supply structure, 12–13
- Seaweeds proteins and amino acid composition
 - EAA, 307–308
 - glutamic and aspartic acid, 308
 - hydrolysis, 308
- factors
 - content, red seaweed, 304, 305
 - green and brown seaweed, content, 304, 305
 - polysaccharides, 304–307
 - use, 303
 - value, 304
- nutritional evaluation
 - AAS, 308–309
 - digestibility, 309
 - green and brown seaweed, 306, 309
 - lysine, 309
 - red seaweed, 305, 309
- Seaweed vitamins, nutraceuticals
 - antioxidant activity
 - carotenoids, 365
 - cerebrovascular diseases, 365
 - compounds, 364
 - food industry, 364
 - low lipid content, 365
 - marine algae, 364
 - neutralizing free radicals, 365–366
 - oxidative forms, 364
 - vitamin C dietary intake, 365–366
 - bioavailability and absorption
 - algal vitamin B12, 362
 - fat-soluble vitamins, 361–362
 - food source, 361
 - factors, vitamin content
 - plant metabolism
 - carotenes content affection, 361
 - concentration-and temperature-dependent processes, 361
 - light and oxygen, 361
 - plant metabolism, 361
 - functions, human body
 - antioxidant activity, 358
 - enzyme cofactors, 358
 - intermediary carbon metabolism, 358–359
 - LDL oxidation, 359
 - provitamin function, 359
 - requirements, human
 - antioxidant activity, 359
 - fat-soluble vitamins, 360
 - RDA, 359
 - vitamins B₁ and B₂, 360
- vitamin composition
 - A, B₂, B₁₂, 362
 - daily requirements, 362
 - DNA methylation, 363
 - Enteromorpha flexuosa* and *Ulva fasciata*, 363
 - Gracilaria changgi*, 364
 - red and green algae, 363–364
- SGLT1. *See* Sodium-dependent transporter 1
- Sodium-dependent transporter 1 (SGLT1), 209
- SPMG. *See* Sulfated polymannurogluronate

SPs. *See* Sulfated polysaccharides

Sterols

- description, 192
- health benefit activities
 - antibacterial, 193–194
 - anticancer, 194–195
 - antidiabetic, 195
 - antihypercholesterolemic, 196
 - antihypertensive, 195–196
 - antioxidant, 194
- marine algae, 192–193
- plant, 192

Sulfated polymannurogluronate (SPMG), 260–261

Sulfated polysaccharides (SPs)

- biological activities, 393
- carrageenan, 237, 238, 392–393
- classification, 237
- fucoidan, 237, 238, 392–393
- medicinal benefits and biological activities
 - anticancer effect, 397
 - antioxidant effect, 394–395
 - antiviral effect, 395–396
 - immunomodulating effect, 396–397
- novel extraction and separation techniques, 393
- polymers, 392–393
- ulvan, 237, 238, 392–393

T

Thrombin time (TT), 236–237

TIMPs. *See* Tissue inhibitors of metalloproteinases

Tissue inhibitors of metalloproteinases (TIMPs), 130

Tororokombu (TK)

- description, 202
- and HFD, 202–203
- and NSK, inhibitory activities
 - alginate, 203, 204
 - alkaline-soluble fraction (AS), 203, 204
 - antiobesity effects, 202–203
 - pancreatic lipase activity, 203

Transforming growth factor

β (TGF- β), 430

TT. *See* Thrombin time

U

Ulvans

- applications, 62
- chemical structure, 61
- description, 218

V

Very low density lipoprotein (VLDL), 341

W

WAT. *See* White adipose tissue

White adipose tissue (WAT), 119–120

Wnt signaling components

- cell proliferation and division, 182
- expression measurement, 184
- IEC-6 cells, 184
- time-course experiment, 182